research

Researchers at Queen’s University Belfast are studying how myelin might be repaired, in an attempt to reverse the damage caused by multiple sclerosis (MS). The more than £2 million, five-year research grant is jointly funded by  the Wellcome Trust, in its first Investigator Award for Northern Ireland, and by the BBSRC, the Biotechnology and Biosciences…

Can we all agree that research studies are important and they are necessary to prove whether a concept works or it doesn’t? Even from the biggest failures, we can learn more. We can also all agree that research has to be done via properly conducted studies to be accepted as…

Gut bacteria and health have been topics of considerable scientific speculation in recent years, and the field of multiple sclerosis (MS) research is no exception. But what do we really know about MS and our intestinal inhabitants? A review, “Emerging Concepts on the Gut Microbiome and Multiple Sclerosis,” published in…

Building on work began in stroke studies and applying it to multiple sclerosis, researchers in France report that an antibody they developed kept the blood-brain barrier intact in cellular and mice MS models despite the presence of inflammation, preventing immune cells from entering the brain. The key to understanding the study…

Women with multiple sclerosis (MS) and people diagnosed with the disease at a younger age are more likely to have a benign course of MS, remaining fully functional for decades after disease onset, according to researchers at the School of Medicine and Biomedical Sciences in New York. Disease modifying drugs were also found…

Low-quality unauthorized generic versions of approved multiple sclerosis (MS) drugs can expose patients to danger, both through their toxic properties and a lack of efficacy that allows the disease to progress, researchers reported in the study, “Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod,” published…

A research project that aims to explore how astrocytes can be manipulated to stop or prevent neurodegeneration has received a grant from the National Stem Cell Foundation (NSCF). The project will be conducted by the The New York Stem Cell Foundation (NYSCF) Research Institute. The work developed by Dr. Valentina…

Do you have any strong feelings about worms? No, not earthworms you find in the garden, or even roundworms or tapeworms that can sometimes be found in animals and humans. What I am talking about is purposely being infected with parasitic worms. OK, it may not be as gross as…

MediciNova recently reported that half of the 255 patients enrolled in a Phase 2b clinical trial (SPRINT-MS) exploring MN-166 (ibudilast) in progressive multiple sclerosis (MS) had completed the 96-week-long treatment. Interim data will be analyzed by the trial’s external Data Safety Monitoring Board later this year, with results…

MediciNova recently reported that half of the 255 patients enrolled in a Phase 2b clinical trial (SPRINT-MS) exploring MN-166 (ibudilast) in progressive multiple sclerosis (MS) had completed the 96-week-long treatment. Interim data will be analyzed by the trial’s external Data Safety Monitoring Board later this year, with results…

Quite a mixed bag in the pick of the week’s news: A drug in development, microbiota in the gut, statins and MS, DMTs and cognitive skills, and images of depression. Endece Granted New U.S. Patent for NDC-1308, Therapy to Induce Remyelination in MS This is a bit of an…

A recent study in the Journal of Medicinal Chemistry and Toxicology reported that the impact of disease-causing free radicals on the human body may be mitigated by wearing special, high-tech “Nanobionic” clothing for just a few hours a day. These clothes are designed to protect the body from…

A link indeed appears to exist between multiple sclerosis (MS) and unusual changes in the bacterial composition of the gut, according to researchers at Brigham and Women’s Hospital (BWH). In their study, “Alterations of the human gut microbiome in multiple sclerosis,” published in the journal Nature Communications,…

Endece was recently issued an additional U.S. patent for its lead investigational product, NDC-1308, being developed to induce remyelination in patients with multiple sclerosis (MS) and prevent disease progression. Currently in late preclinical development, NDC-1308 is designed to repair the myelin sheath of demyelinated axons (nerve fibers), a major cause…

Disease-modifying therapies, a group of treatments for people with relapsing-remitting multiple sclerosis (RRMS), work to stabilize patients’ cognitive functions just as they do their physical symptoms. Research, conducted over the course of a year, also reported no differences between two types of DMTs, Gilenya (fingolimod) and Tysabri (natalizumab). The study, “…

Inflammation in a brain region called the hippocampus might explain why patients with multiple sclerosis (MS) suffer from depression far more often than patients with other chronic brain diseases. The findings, described in the report “Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis,” published in the…

When I see a new drug for MS come to market, I only think of the company behind that product – it could be one of the big names such as Genentech, Genzyme, EMD Serono, Biogen, or one of the many other players in the field.  I never stopped to…

Fecal samples from a group of people with relapsing-remitting multiple sclerosis (RRMS) showed evidence of a different gut microbiota than that found in healthy controls, and may be a non-genetic reason for the altered immune system responses seen in MS patients. The study, “Multiple sclerosis patients have…

One of the world’s most commonly used medications — the cholesterol-lowering drug simvastatin — was found to affect the immune system in a way that can be explored to treat inflammatory diseases such as multiple sclerosis (MS). Researchers have earlier noted that simvastatin, a cholesterol-lowering drug, is beneficial for MS…

Opinions voiced by multiple sclerosis (MS) patients as to what they most want from, and like in, an MS treatment differ widely, although delaying progression and relapses — and minimizing serious side effects — clearly score high, according to new research from the University of British Columbia in Canada. The study, “Quantitative…

Detecting brain atrophy in multiple sclerosis (MS) patients requires high quality scans, too expensive and complicated for routine clinical use. But this may change with a new software that simplifies the calculation of brain atrophy based on data from routine magnetic resonance images (MRI). The new tool and its benefits were recently described…

The Institute of Clinical and Economic Review (ICER) released the early draft of a paper intended to inform a future report evaluating the effectiveness and value of disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS). The paper, called a draft scoping document, is titled “Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Effectiveness and…

Disabling tremors can affect as many as half of all people with multiple sclerosis (MS), but they are inadequately treated because of limited therapeutic options and are not sufficiently being studied, researchers at the University of Alabama at Birmingham reported. Their report, “Symptomatic Management of Multiple Sclerosis-Associated Tremor Among…

A few months ago I had the honor of meeting David Lacks, a grandson of Henrietta Lacks. It was at a large meeting and not everyone in the room understood his link to our medical care; the people who already knew about grandmother had most probably read the book…

As Multiple Sclerosis News Today reported in mid-July, Endece Neural was issued an additional U.S. patent for its lead investigational product, NDC-1308. The drug is under development to repair the myelin sheath damaged in multiple sclerosis (MS), a major causing disease progression and increasing disability. The sheath, an…

As interesting as it can be for patients with MS who hear about work being done to find the causes of multiple sclerosis, what we really want to see is research that is carried out to find a cure. Nothing more, nothing less. Of course, the development of new treatments…

Researchers working with magnetic resonance imaging (MRI) are often faced with a problem: an average MRI brain scan produces a considerable amount of images (around 600 megabytes), but half carry distortions that make them unreadable. These “phase images,” as they are known, are usually discarded and their insights lost. Now, the work of researchers…

A therapeutic vaccine for patients with multiple sclerosis (MS), called Xemys, is showing positive results in pre-clinical and clinical trials, and is soon to enter Phase 3 clinical testing. Xemys was developed by researchers at the Institute of Bioorganic Chemistry of the Russian Academy of Sciences and their colleagues. While traditional vaccines are…

The president of Colorado State University (CSU), Tony Frank, will be accepting the Norman Cohn Hope Award on behalf of his university, recognizing its work in advancing research into multiple sclerosis and helping people with the disease. The ceremony will take place at the Annual MS Society Dinner of Champions, set for Sept.

The complement system, a part of our non-adaptable (innate) immune defenses, is activated in lesions inside the brain’s gray matter and may well contribute to the relentless progression of multiple sclerosis (MS), researchers report. The findings offer new insights into mechanisms driving the development of this disease — particularly its primary progressive forms.